168823-76-5

Basic information

• Product Name: Pyridine, 5-bromo-2-(chloromethyl)- (9CI)
• Synonyms: Pyridine, 5-bromo-2-(chloromethyl)- (9CI);5-bromo-2-(chloromethyl)pyridine
• CAS NO: 168823-76-5
• Molecular Formula: C₆H₅BrClN
• Molecular Weight: 206.4676
• Product Categories: PYRIDINE
• Mol File: 168823-76-5.mol

Chemical Properties

• Boiling Point: 243.4 °C at 760 mmHg
• Flash Point: 101 °C
• Appearance: /
• Density: 1.631 g/cm³
• Vapor Pressure: 0.05mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.35±0.22(Predicted)
• CAS DataBase Reference: Pyridine, 5-bromo-2-(chloromethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 5-bromo-2-(chloromethyl)- (9CI)(168823-76-5)
• EPA Substance Registry System: Pyridine, 5-bromo-2-(chloromethyl)- (9CI)(168823-76-5)

Safety Data

• Hazardous Substances Data: 168823-76-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Pyridine, 5-bromo-2-(chloromethyl)(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Production:
Pyridine, 5-bromo-2-(chloromethyl)(9CI) is also utilized in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural products to enhance crop protection and yield.
Used in Organic Compounds Synthesis:
Pyridine, 5-bromo-2-(chloromethyl)(9CI) serves as an intermediate in the synthesis of other organic compounds, expanding its applications in the chemical industry.

InChI:InChI=1/C6H5BrClN/c7-5-1-2-6(3-8)9-4-5/h1-2,4H,3H2

Upstream product

• 29682-15-3 methyl 5-bromopicolinate 
• 31181-64-3 5-bromo-2-methyl-pyridine-N-oxide 
• 3430-13-5 5-bromo-2-methylpyridine 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 145218-19-5 5-bromo-2-(bromomethyl)pyridine 
• 900186-88-1 trifluoro-acetic acid 5-bromo-pyridin-2-ylmethyl ester 
• 88139-91-7 (5-bromopyridin-2-yl)methanol 

Downstream Products

• 1253579-14-4 5-(5-bromo-picol-2-yl)-10,15,20-trimesitylporphinato-Zn(II) 
• 380893-73-2 [(5-bromo-2-pyridinyl)methyl]-phosphonic acid diethyl ester 
• 1566292-79-2 5-brom-2-methylsulfanylmethylpyridine 
• 1454904-49-4 2,2-difluoro-N-[(1S,2R)-1-fluoromethyl-2-hydroxy-2-(4-{6-[(methanesulfonylmethoxyamino)methyl]pyridin-3-yl}phenyl)ethyl]acetamide 
• 312325-72-7 2-(5-bromopyridin-2-yl)acetonitrile 
• 1257426-00-8 (6S)-2-nitro-6-({5-[4-(trifluoromethoxy)phenyl]-2-pyridinyl}methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1263417-11-3 (6S)-2-nitro-6-[(5-{[4-(trifluoromethoxy)phenyl]ethynyl}pyridin-2-yl)methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 

Relevant articles and documents

NOVEL PHENICOL ANTIBACTERIAL AGENTS

The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical compositions containing these novel compounds, and methods for the preparation of these compounds.

PHENICOL ANTIBACTERIALS

The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.

Dynamics of closure of zinc bis-porphyrin molecular tweezers with copper(II) ions and electron transfer

Zinc bis-porphyrin molecular tweezers composed of a N4 spacer bound through pyridyl units to the meso position of porphyrins were synthesized, and the tweezers are closed by the coordination of a copper(II) ion inside the spacer ligand. The effect of the π-π interaction between the porphyrin rings in the closed conformation on the absorption spectra of multi-electron oxidized species and the reduction potentials were clarified by chemical and electrochemical oxidation of the closed form of the zinc bis-porphyrin molecular tweezers in comparison with the open form without copper(II) ion and the corresponding porphyrin monomer. The shifts in redox potentials and absorption spectrum of the porphyrin dication indicate a strong electronic interaction between the two oxidized porphyrins in the closed form, whereas there is little interaction between them in the neutral form. The dynamics of copper(II) ion coordination and subsequent electron transfer was examined by using a stopped-flow UV/Vis spectroscopic technique. It was confirmed that coordination of copper(II) occurs prior to electron-transfer oxidation of the closed form of the zinc bis-porphyrin molecular tweezers.

Inhibition of 1-deoxy-d-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies

1-Deoxy-d-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY

The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5 H-imidazo[2,1-b][1,3]oxazine (PA-824)

New heterocyclic analogues of the potent biphenyl class derived from antitubercular drug PA-824 were prepared, aiming to improve aqueous solubility but maintain high metabolic stability and efficacy. The strategy involved replacement of one or both phenyl

Towards the synthesis of substituted porphyrins by a pyridyl group bearing a reactive functionality

Pyridyl-substituted porphyrins bearing a reactive functionality were prepared via Suzuki cross-coupling reactions and resulted in very good yields. These compounds are precursors of new porphyrin architectures able to coordinate two metals: one in the porphyrin core and the second around the pyridyl moiety. During the coupling reactions, a higher reactivity of a chloro picolyl group was evidenced compared to a bromo function on the same reacting molecule.

Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate

This application discloses a novel process for the preparation of phosphonate esters useful as intermediates in the preparation of himbacine analogs, themselves useful as thrombin receptor antagonists. The chemistry taught herein can be exemplified by the following scheme: wherein R9 is selected from alkyl, aryl heteroaryl and arylalkyl groups having 1 to 10 carbon atoms, and R11 is selected independently for each occurrence from alkyl, aryl heteroaryl and arylalkyl groups having 1 to 10 carbon atoms and hydrogen, X2 is Cl, Br, or I; X3 is selected from Cl and Br; and PdLn is a supported palladium metal catalyst or a soluble heterogeneous palladium catalyst. The L-derivatizing reagent is a moiety which converts the alcohol functional group of compound 137D to any leaving group which can be displaced by a triorgano-phosphite phosphonating agent.

HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula: (I); or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-α or combinations thereof.

EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS

The application discloses a novel process for the preparation of himbacine analogs useful as thrombin receptor antagonists. The process is based in part on the use of a base-promoted dynamic epimerization of a chiral nitro center. The chemistry taught her